Kairos Biotech is developing a pipeline of proprietary small molecules for next-generation immunotherapy and diagnostics aimed at enhancing transplant options. Their approach targets barriers to transplantation by improving immune response and compatibility through novel therapeutic applications.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EHFounders
Product
Problem
Organ transplant rejection remains a significant challenge, often requiring long-term immunosuppression that increases the risk of infection and other complications. Current diagnostic methods for assessing transplant compatibility and immune response lack the sensitivity and specificity needed for personalized treatment strategies.
Solution
Kairos Biotech is developing a portfolio of small-molecule immunotherapies and diagnostics designed to improve transplant outcomes. Their approach focuses on modulating the immune response to enhance transplant compatibility and reduce the likelihood of rejection. By targeting key pathways involved in immune regulation, Kairos Biotech aims to create more effective and targeted therapies that minimize the need for broad immunosuppression. The company's theranostic strategy integrates diagnostic tools with therapeutic interventions, enabling clinicians to monitor patient response and tailor treatment plans accordingly.
Target Audience
The primary target audience includes transplant centers, physicians specializing in transplantation, and patients undergoing or awaiting organ transplantation.
Features
- Proprietary small-molecule compounds designed to modulate the immune system
- Targeted therapies aimed at enhancing transplant compatibility
- Diagnostic assays for assessing immune response and predicting rejection risk
- Theranostic approach integrating diagnostics and therapeutics for personalized treatment